Xu Liang

发表

Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.

B. Shao, Huiping Li, G. Song, 2017, Breast.

HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro

T. Shen, Xiao-Lin Lin, Jun Ren, 2012, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Receptor Conversion between Primary Tumors and Distant Metastases in 121 Cases of Metastatic Breast Cancer

B. Shao, Huiping Li, L. Di, 2013 .

Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study.

B. Shao, Huiping Li, G. Song, 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer.

Zhiyuan Hu, H. Rugo, B. Shao, 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences

H. Lyerly, L. Che, Jun Ren, 2013, Clinical and Translational Oncology.

Non‐genetic risk factors and predicting efficacy for docetaxel–drug‐induced liver injury among metastatic breast cancer patients

Z. Wang, H. Lyerly, Jun Ren, 2012, Journal of gastroenterology and hepatology.

Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients

L. Che, Jun Ren, J. Jia, 2011, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?

Huiping Li, F. Lerebours, C. Callens, 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis

Huiping Li, C. Geng, Hongmei Zhao, 2021, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors

B. Shao, Huiping Li, L. Di, 2022, Frontiers in Oncology.

Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients

B. Shao, Z. Wang, H. Lyerly, 2013, Clinical and Translational Oncology.

Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer

B. Shao, Huiping Li, G. Song, 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

S. Vacher, I. Bièche, V. Bernard, 2018, Breast Cancer Research.

Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer.

Huiping Li, L. Di, Ying Yan, 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis

B. Shao, Huiping Li, Hanfang Jiang, 2021, Anti-cancer drugs.

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing

Huiping Li, Jianjun Yu, S. Jia, 2021, Cancer management and research.

Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer

J. Yu, Huiping Li, Jianjun Yu, 2020, Breast.

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

J. Lemonnier, V. Bécette, M. Mouret-Reynier, 2018, Journal of Hematology & Oncology.

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients

Huiping Li, L. Di, G. Song, 2014, Oncology letters.

Clinicopathological features and prognosis of patients with pregnancy‐associated breast cancer: A matched case control study

B. Shao, Huiping Li, L. Di, 2021, Asia-Pacific journal of clinical oncology.

Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)

B. Shao, Huiping Li, L. Di, 2021, Cancer medicine.

A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view

Ying Yan, Xu Liang, Guo-hong Song, 2022, Translational Breast Cancer Research.

Gemcitabine based combination regimens for treatment of refractory advanced breast cancer

L. Che, J. Jia, L. Di, 2008 .

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting

B. Shao, Huiping Li, A. Zhu, 2023, Frontiers in Oncology.

Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis

Huiping Li, Xu Liang, Xinyu Gui, 2023, Cancer medicine.

Real‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis

L. Di, Xu Liang, Xinyu Gui, 2024, Cancer.

Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer

B. Shao, Huiping Li, S. Jia, 2024, British journal of cancer.